eTheRNA
PrivateLast Round
Series B
Extension
Aug 23, 2022
Total Funding Raised
$104M
Company Overview
eTheRNA is a biotechnology company focused on developing targeted and safe mRNA therapies to enhance the human immune system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
eTheRNA Comps
Public and private peers based on sector, stage, and business model.
eTheRNA Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 23, 2022 | ||||
| Series B | Jun 16, 2020 | ||||
| Series A | Mar 14, 2016 |
Key People
Founding team and executive leadership
eTheRNA Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yijing Capital | Series B |
| Omega Funds | Series A, Series B |
| EQT Life Sciences | Series B Extension, Series B, Series A |
| Fund+ | Series B Extension, Series A, Series B |
| Novalis LifeSciences | Series B Extension, Series B |
| PMV | Series B Extension, Series B, Series A |
| Boehringer Ingelheim Venture Fund | Series A, Series B |
eTheRNA Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about eTheRNA's valuation, stock price, and market status.
